ERBB2 and cancer: In fact, Lee et al. identified several small molecule inhibitors of Sema3C that reduce the phosphorylation of EGFR, HER2/ErbB2, SHC, and MAPK, collectively providing evidence in experimental models that Sema3C inhibition may represent a promising avenue for developing targeted therapies against PC and possibly other cancer types 91.